TCR2 Therapeutics

TCR , Inc. is a discovery stage pharmaceutical company focused on engineering T cells for cancer therapy. The company's vast expertise in T cell engagement and a deep understanding of T cell receptor biology enabled the creation of a novel first-in-class approach that is highly differentiated from CAR-T cells and from T cells engineered to express defined TCR alpha/beta chains. TCR was founded by MPM Capital and has scientific operations in Kendall Square, Cambridge, Massachusetts to leverage best-in-class technologies and nucleate top-tier academic laboratories around the world.
Company Growth (employees)
Type
Private
HQ
Cambridge, US
Founded
2015
Size (employees)
22 (est)+10%
Website
tcr2.com
TCR2 Therapeutics was founded in 2015 and is headquartered in Cambridge, US

TCR2 Therapeutics Office Locations

TCR2 Therapeutics has an office in Cambridge
Cambridge, US (HQ)
675 W Kendall St

TCR2 Therapeutics Data and Metrics

Summary Metrics

Founding Date

2015

Total Funding

$48.3 m

Latest funding size

$44.5 m

Time since last funding

8 months

Investors

TCR2 Therapeutics's latest funding round in December 2016 was reported to be $44.5 m. In total, TCR2 Therapeutics has raised $48.3 m

TCR2 Therapeutics Company Life and Culture

You may also be interested in